India Pharma Outlook Team | Monday, 26 October 2026
AIIMS Nagpur secures Rs 30 crore sanction from the National Centre for Disease Control for a Biosafety Level-III laboratory. This marks a decisive step beyond routine infrastructure funding.
This investment positions Maharashtra to reduce reliance on distant national facilities, particularly the National Institute of Virology in Pune, and build regional self-reliance for detecting high-risk and zoonotic pathogens.
The move arrives as deforestation, expanding human-wildlife contact and climate shifts reshape the risk landscape across Vidarbha and central India.
In essence, the project advances pathogen sovereignty by enabling local detection, sequencing and response instead of shipping samples elsewhere.
The Rs 30 crore NCDC allocation covers infrastructure alone. Manpower and equipment will draw from separate budgets. Space already stands earmarked, and the laboratory should become operational in about a year.
Alongside this, AIIMS Nagpur converts its existing Virus Research and Diagnostic Laboratory into a full Infectious Disease Research and Diagnostic Laboratory at a cost of Rs 17 crore, funded by ICMR-DHR.
The upgraded facility will handle bacteriology, mycology, parasitology and virology while expanding the range of infections under test. Officials expect it to function within three months.
AIIMS Nagpur already contributes to national surveillance programs and has helped grant PCR-testing accreditation to more than 250 laboratories, giving the dual upgrade a ready foundation.
Also Read: India's 30% Anti-Cancer Drug Margin Cap: What It Means for Pharma
Advanced high-risk testing currently depends heavily on NIV Pune. The new BSL-III laboratory will serve as a decentralized sentinel for Vidarbha and central India, shortening the distance between sample and diagnosis.
AIIMS Executive Director Prashant Joshi notes that the facility “will reduce dependence on National Institute of Virology (NIV), Pune, for advanced testing and help strengthen Maharashtra’s capacity for infectious disease surveillance and research.”
He links the timing directly to ecological pressure: “Human-animal interface is increasing because of deforestation. We are invading the habitat of animals. Climate change and deforestation are very important factors.”
Microbiology Head Meena Mishra stresses the dual approach required for early warning. “If the incidence of a disease is increasing, it should be picked up through proper syndromic surveillance as well as genomics at an early stage so that proper preventive measures can be implemented.”
Together, these capabilities allow the institute to identify unusual illness patterns and track mutations through whole genome sequencing.
The upgrades will deliver faster turnaround for critical samples and strengthen regional input into national surveillance networks. AIIMS Nagpur can evolve from a diagnostic center into a research and training hub that builds local expertise. The investment quietly embeds lessons from recent outbreak years by placing high-containment capacity closer to emerging risk zones without relying solely on central laboratories.
With this Rs 30 crore commitment, Maharashtra quietly constructs the infrastructure needed to detect the next threat closer to home. The dual BSL-III and IRDL upgrades shift the state from sample-sending dependence toward genuine regional biosafety capacity, an incremental but consequential advance in pathogen preparedness.
.jpg)
